Koninklijke DSM (OTCMKTS:RDSMY) – Equities researchers at Jefferies Financial Group issued their Q1 2021 EPS estimates for Koninklijke DSM in a report issued on Monday, February 22nd. Jefferies Financial Group analyst L. Alexander forecasts that the basic materials company will earn $0.39 per share for the quarter. Jefferies Financial Group also issued estimates for Koninklijke DSM’s Q2 2021 earnings at $0.39 EPS, Q3 2021 earnings at $0.40 EPS and Q4 2021 earnings at $0.31 EPS.
RDSMY has been the subject of a number of other research reports. Sanford C. Bernstein downgraded Koninklijke DSM from a “market perform” rating to an “underperform” rating in a research report on Tuesday, January 12th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Koninklijke DSM in a research report on Tuesday, November 10th. Barclays reiterated an “overweight” rating on shares of Koninklijke DSM in a research report on Wednesday, February 17th. Credit Suisse Group restated an “outperform” rating on shares of Koninklijke DSM in a research report on Wednesday, February 17th. Finally, UBS Group restated a “buy” rating on shares of Koninklijke DSM in a research report on Wednesday, February 17th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $49.00.
About Koninklijke DSM
Koninklijke DSM N.V., a science-based company, engages in nutrition, health, and sustainable living businesses in the Netherlands, rest of Europe, North America, Latin America, China, India, Japan, rest of Asia, and internationally. It operates through Nutrition, Materials, and Innovation Center segments.
Read More: Trading Halts
Receive News & Ratings for Koninklijke DSM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke DSM and related companies with MarketBeat.com's FREE daily email newsletter.